|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||542.50 - 568.00|
|52 Week Range||304.88 - 601.84|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||76.62|
|Earnings Date||Nov 02, 2023|
|Forward Dividend & Yield||4.52 (0.79%)|
|Ex-Dividend Date||Aug 14, 2023|
|1y Target Est||569.28|
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Toyota Motor Corporation (TM) and Accenture plc (ACN).
Pharmaceutical majors Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) have experienced a significant increase in their market value on Thursday, driven by the potential of their weight-loss drugs, GLP-1s, to address the global obesity epidemic. This optimism has propelled sales forecasts into the hundreds of billions. However, this same optimism has negatively impacted companies that have traditionally profited from treating obesity-related complications.
Leading pharmaceutical companies, Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY), are anticipated to see significant revenue growth from their newly developed obesity drugs, according to financial analysts' predictions. These medications, known as GLP-1 receptor agonists, are considered the safest and most effective weight-loss drugs currently available. They offer potential body weight reductions of up to 20% and could also diminish patients' risk of heart attack or stroke.